Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.

Trial Details

NCT ID
NCT07357519
Phase
PHASE1 / PHASE2
Sponsor
Lantheus Medical Imaging
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • LNTH2403 Phase 1 dose
  • Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Histopathologic documented diagnosis of R/R osteosarcoma
  • Must have disease characterized by at least one of the following (Participants meeting only (b.), only (c.), or only (b. and c.) must be discussed …
  • Measurable as defined in RECIST 1.1
  • Evaluable non-measurable disease as per RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →